Publikationen

Über den E-Newsletter wird in jeder Ausgabe eine Auswahl der wichtigsten Publikationen der vergangenen zwei Monate aus dem Netzwerk veröffentlicht. Die Auswahl wird durch das Informationszentrum getroffen. Pünktlich zum Erscheinen des E-Newsletters finden Sie die jeweils aktuellen Publikationen auch auf dieser Seite.


Becker H, Suciu S, Ruter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Muus P, Pfluger KH, Hagemeijer A, Schaefer HE, Fiaccadori V, Baron F, Ganser A, Aul C, de Witte T, Wijermans PW, Lubbert M. Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG). Ann Hematol. 2015;94(12):2003-13. PMID: 26400023. doi: 10.1007/s00277-015-2489-6.

Bozic T, Lin Q, Frobel J, Wilop S, Hoffmann M, Muller-Tidow C, Brummendorf TH, Jost E, Wagner W. DNA-methylation in C1R is a prognostic biomarker for acute myeloid leukemia. Clin Epigenetics. 2015;7(116. PMID: 26539253. doi: 10.1186/s13148-015-0153-6.

Braulke F, Muller-Thomas C, Gotze K, Platzbecker U, Germing U, Hofmann WK, Giagounidis AA, Lubbert M, Greenberg PL, Bennett JM, Sole F, Slovak ML, Ohyashiki K, Le Beau MM, Tuchler H, Pfeilstocker M, Hildebrandt B, Aul C, Stauder R, Valent P, Fonatsch C, Bacher U, Trumper L, Haase D, Schanz J. Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control group. Genes Chromosomes Cancer. 2015;54(12):809-17. PMID: 26355708. doi: 10.1002/gcc.22292.

Chatain N, Perera RC, Rossetti G, Rossa J, Carloni P, Schemionek M, Haferlach T, Brummendorf TH, Schnittger S, Koschmieder S. Rare FLT3 deletion mutants may provide additional treatment options to patients with AML: an approach to individualized medicine. Leukemia. 2015;29(12):2434-8. PMID: 26012842. doi: 10.1038/leu.2015.131.

Fabarius A, Kalmanti L, Dietz CT, Lauseker M, Rinaldetti S, Haferlach C, Gohring G, Schlegelberger B, Jotterand M, Hanfstein B, Seifarth W, Hanel M, Kohne CH, Lindemann HW, Berdel WE, Staib P, Muller MC, Proetel U, Balleisen L, Goebeler ME, Dengler J, Falge C, Kanz L, Burchert A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Brummendorf TH, Edinger M, Hofmann WK, Pfirrmann M, Hasford J, Krause S, Hochhaus A, Saussele S, Hehlmann R. Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. Ann Hematol. 2015;94(12):2015-24. PMID: 26385387. doi: 10.1007/s00277-015-2494-9.

Kroger N, Bornhauser M, Stelljes M, Pichlmeier U, Trenschel R, Schmid C, Arnold R, Martin H, Heinzelmann M, Wolschke C, Meyer RG, Bethge W, Kobbe G, Ayuk F, Gokbuget N, Holzer D, Zander A, Beelen D. Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with ALL: a phase II-study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL). Bone Marrow Transplant. 2015;50(12):1503-7. PMID: 26367236. doi: 10.1038/bmt.2015.202.

Lichtenegger FS, Kondla I, Krempasky M, Weber AL, Herold T, Krupka C, Spiekermann K, Schneider S, Buchner T, Berdel WE, Wormann BJ, Hiddemann W, Subklewe M. RNA and protein expression of herpesvirus entry mediator (HVEM) is associated with molecular markers, immunity-related pathways and relapse-free survival of patients with AML. Cancer Immunol Immunother. 2015;64(12):1505-15. PMID: 26377688. doi: 10.1007/s00262-015-1755-8.

List AF, Bennett JM, Sekeres MA, Skikne B, Fu T, Shammo JM, Nimer SD, Knight RD, Giagounidis A. Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS. Leukemia. 2015;29(12):2452. PMID: 26648407. doi: 10.1038/leu.2015.312.

Meggendorfer M, de Albuquerque A, Nadarajah N, Alpermann T, Kern W, Steuer K, Perglerova K, Haferlach C, Schnittger S, Haferlach T. Karyotype evolution and acquisition of FLT3 or RAS pathway alterations drive progression of myelodysplastic syndrome to acute myeloid leukemia. Haematologica. 2015;100(12):e487-90. PMID: 26294738. doi: 10.3324/haematol.2015.127985.

Naumann N, Schwaab J, Metzgeroth G, Jawhar M, Haferlach C, Gohring G, Schlegelberger B, Dietz CT, Schnittger S, Lotfi S, Gartner M, Dang TA, Hofmann WK, Cross NC, Reiter A, Fabarius A. Fusion of PDGFRB to MPRIP, CPSF6, and GOLGB1 in three patients with eosinophilia-associated myeloproliferative neoplasms. Genes Chromosomes Cancer. 2015;54(12):762-70. PMID: 26355392. doi: 10.1002/gcc.22287.

Rollig C, Serve H, Huttmann A, Noppeney R, Muller-Tidow C, Krug U, Baldus CD, Brandts CH, Kunzmann V, Einsele H, Kramer A, Schafer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, Herbst R, Hanel M, Kiani A, Frickhofen N, Kullmer J, Kaiser U, Link H, Geer T, Reichle A, Junghanss C, Repp R, Heits F, Durk H, Hase J, Klut IM, Illmer T, Bornhauser M, Schaich M, Parmentier S, Gorner M, Thiede C, von Bonin M, Schetelig J, Kramer M, Berdel WE, Ehninger G. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015;16(16):1691-9. PMID: 26549589. doi: 10.1016/s1470-2045(15)00362-9.

Schneider V, Zhang L, Rojewski M, Fekete N, Schrezenmeier H, Erle A, Bullinger L, Hofmann S, Gotz M, Dohner K, Ihme S, Dohner H, Buske C, Feuring-Buske M, Greiner J. Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic T cells against immunogenic leukemia-associated antigens. Int J Cancer. 2015;137(9):2083-92. PMID: 25912930. doi: 10.1002/ijc.29583.

Wenn K, Tomala L, Wilop S, Vankann L, Hasenbank C, Frank O, Hochhaus A, Giles FJ, Lange T, Muller MC, Koschmieder S, Beier F, Ziegler P, Brummendorf TH. Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib. Leukemia. 2015;29(12):2402-4. PMID: 26369986. doi: 10.1038/leu.2015.245.

Zugmaier G, Gokbuget N, Klinger M, Viardot A, Stelljes M, Neumann S, Horst HA, Marks R, Faul C, Diedrich H, Reichle A, Bruggemann M, Holland C, Schmidt M, Einsele H, Bargou RC, Topp MS. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment. Blood. 2015;126(24):2578-84. PMID: 26480933. doi: 10.1182/blood-2015-06-649111.


Aliperta R, Cartellieri M, Feldmann A, Arndt C, Koristka S, Michalk I, von Bonin M, Ehninger A, Bachmann J, Ehninger G, Bornhauser M, Bachmann MP. Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts. Blood Cancer J. 2015;5(e348. PMID: 26383821. doi: 10.1038/bcj.2015.73.

Frobel J, Hartwig S, Jourdain S, Fischer JC, Zilkens C, Kundgen A, Suckau D, Germing U, Czibere A, Lehr S. Deep serum discoveries: SDF-1alpha and HSA fragments in myelodysplastic syndromes. Am J Hematol. 2015;90(9):E185-7. PMID: 26010554. doi: 10.1002/ajh.24070.

Ganster C, Shirneshan K, Salinas-Riester G, Braulke F, Schanz J, Platzbecker U, Haase D. Influence of total genomic alteration and chromosomal fragmentation on response to a combination of azacitidine and lenalidomide in a cohort of patients with very high risk MDS. Leuk Res. 2015;39(10):1079-87. PMID: 26278198. doi: 10.1016/j.leukres.2015.06.011.

Gentner B, Pochert N, Rouhi A, Boccalatte F, Plati T, Berg T, Sun SM, Mah SM, Mirkovic-Hosle M, Ruschmann J, Muranyi A, Leierseder S, Argiropoulos B, Starczynowski DT, Karsan A, Heuser M, Hogge D, Camargo FD, Engelhardt S, Dohner H, Buske C, Jongen-Lavrencic M, Naldini L, Humphries RK, Kuchenbauer F. MicroRNA-223 dose levels fine tune proliferation and differentiation in human cord blood progenitors and acute myeloid leukemia. Exp Hematol. 2015;43(10):858-68.e7. PMID: 26163797. doi: 10.1016/j.exphem.2015.05.018.

Giagounidis A. Where Does Lenalidomide Fit in Non-del(5q) MDS? Curr Hematol Malig Rep. 2015;10(3):303-8. PMID: 26169489. doi: 10.1007/s11899-015-0275-0.

Heuser M, Meggendorfer M, Cruz MM, Fabisch J, Klesse S, Kohler L, Gohring G, Ganster C, Shirneshan K, Gutermuth A, Cerny-Reiterer S, Kronke J, Panagiota V, Haferlach C, Koenecke C, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Ehrlich S, Stamer K, Dohner K, Valent P, Schlegelberger B, Kroeger N, Ganser A, Haase D, Haferlach T, Thol F. Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q. Leukemia. 2015;29(9):1942-5. PMID: 25792355. doi: 10.1038/leu.2015.49.

Lauseker M, Schemenau J, Strupp C, Kundgen A, Gattermann N, Hasford J, Germing U. In patients with myelodysplastic syndromes with del(5q), factors other than age and sex contribute to the prognostic advantage, which diminishes over time. Br J Haematol. 2015;170(5):687-93. PMID: 25960152. doi: 10.1111/bjh.13496.

Manukjan G, Ripperger T, Santer L, von Neuhoff N, Ganser A, Schambach A, Schlegelberger B, Steinemann D. Expression of the ETS transcription factor GABPalpha is positively correlated to the BCR-ABL1/ABL1 ratio in CML patients and affects imatinib sensitivity in vitro. Exp Hematol. 2015;43(10):880-90. PMID: 26072332. doi: 10.1016/j.exphem.2015.05.011.

Sauer T, Arteaga MF, Isken F, Rohde C, Hebestreit K, Mikesch JH, Stelljes M, Cui C, Zhou F, Gollner S, Baumer N, Kohler G, Krug U, Thiede C, Ehninger G, Edemir B, Schlenke P, Berdel WE, Dugas M, Muller-Tidow C. MYST2 acetyltransferase expression and Histone H4 Lysine acetylation are suppressed in AML. Exp Hematol. 2015;43(9):794-802.e4. PMID: 26072331. doi: 10.1016/j.exphem.2015.05.010.

Schemenau J, Baldus S, Anlauf M, Reinecke P, Braunstein S, Blum S, Nachtkamp K, Neukirchen J, Strup C, Aul C, Haas R, Gattermann N, Germing U. Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplastic syndromes. Eur J Haematol. 2015;95(3):181-9. PMID: 25600827. doi: 10.1111/ejh.12512.

Schneider S, Strumpf A, Schetelig J, Wunderlich G, Ehninger G, Kotzerke J, Bornhauser M. Reduced-Intensity Conditioning Combined with (188)Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of In Vivo T Cell Depletion. Biol Blood Marrow Transplant. 2015;21(10):1754-60. PMID: 26001695. doi: 10.1016/j.bbmt.2015.05.012.

Schrenk KG, Schnetzke U, Stegemann K, von Lilienfeld-Toal M, Hochhaus A, Scholl S. Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia. J Cancer Res Clin Oncol. 2015;141(9):1661-8. PMID: 25800622. doi: 10.1007/s00432-015-1962-x.

Schwaab J, Umbach R, Metzgeroth G, Naumann N, Jawhar M, Sotlar K, Horny HP, Gaiser T, Hofmann WK, Schnittger S, Cross NC, Fabarius A, Reiter A. KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance. Am J Hematol. 2015;90(9):774-7. PMID: 26017288. doi: 10.1002/ajh.24075.

Wermke M, Gloaguen S, Platzbecker U. Preparing Patients With Myelodysplastic Syndrome for Transplant When Is Pre-transplant Cytoreductive Therapy Appropriate? Curr Hematol Malig Rep. 2015;10(3):329-33. PMID: 26126601. doi: 10.1007/s11899-015-0276-z.


Brauer-Hartmann D, Hartmann JU, Wurm AA, Gerloff D, Katzerke C, Verga Falzacappa MV, Pelicci PG, Muller-Tidow C, Tenen DG, Niederwieser D, Behre G. PML/RARalpha-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia. Cancer Res. 2015;75(16):3411-24. PMID: 26041820. doi: 10.1158/0008-5472.can-14-3521.

Neukirchen J, Nachtkamp K, Schemenau J, Aul C, Giagounidis A, Strupp C, Kuendgen A, Kobbe G, Haas R, Germing U. Change of prognosis of patients with myelodysplastic syndromes during the last 30 years. Leuk Res. 2015;39(7):679-83. PMID: 25929166. doi: 10.1016/j.leukres.2015.04.001.

Platzbecker U. Which prognostic score in MDS? Both! Leukemia. 2015;29(7):1447. PMID: 25907693. doi: 10.1038/leu.2015.92.

Saussele S, Krauss MP, Hehlmann R, Lauseker M, Proetel U, Kalmanti L, Hanfstein B, Fabarius A, Kraemer D, Berdel WE, Bentz M, Staib P, de Wit M, Wernli M, Zettl F, Hebart HF, Hahn M, Heymanns J, Schmidt-Wolf I, Schmitz N, Eckart MJ, Gassmann W, Bartholomaus A, Pezzutto A, Leibundgut EO, Heim D, Krause SW, Burchert A, Hofmann WK, Hasford J, Hochhaus A, Pfirrmann M, Muller MC. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood. 2015;126(1):42-9. PMID: 25918346. doi: 10.1182/blood-2015-01-617993.

Schnorfeil FM, Lichtenegger FS, Emmerig K, Schlueter M, Neitz JS, Draenert R, Hiddemann W, Subklewe M. T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment. J Hematol Oncol. 2015;8(93. PMID: 26219463. doi: 10.1186/s13045-015-0189-2.

Thiel A, Schetelig J, Ponisch W, Schafer-Eckart K, Aulitzky W, Peter N, Schulze A, Maschmeyer G, Neugebauer S, Herbst R, Hanel A, Morgner A, Kroschinsky F, Bornhauser M, Lange T, Wilhelm M, Niederwieser D, Ehninger G, Fiedler F, Hanel M. Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL). Ann Oncol. 2015;26(7):1434-40. PMID: 25922062. doi: 10.1093/annonc/mdv205.

Thol F, Schlenk RF, Heuser M, Ganser A. How I treat refractory and early relapsed acute myeloid leukemia. Blood. 2015;126(3):319-27. PMID: 25852056. doi: 10.1182/blood-2014-10-551911.

Erstellt von: Hehn (Informationszentrum) am 15.07.2014, letzte Änderung: 16.01.2019